We could not find any results for:
Make sure your spelling is correct or try broadening your search.
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash...
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to...
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments...
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the...
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base...
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S...
By Denny Jacob Xoma will make a $1 million milestone payment to LadRx following the U.S. Food and Drug Administration's acceptance of Zevra Therapeutics' new drug application for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.95 | 3.88389206868 | 24.46 | 26.79 | 24.46 | 10265 | 25.67862752 | CS |
4 | 1.36 | 5.65488565489 | 24.05 | 27 | 23.4401 | 13473 | 25.50878492 | CS |
12 | 5.21 | 25.7920792079 | 20.2 | 27 | 19.5 | 18546 | 24.28765136 | CS |
26 | 7.88 | 44.9515116942 | 17.53 | 27 | 14.27 | 24479 | 20.22068421 | CS |
52 | 7.03 | 38.2480957563 | 18.38 | 27 | 13.48 | 30075 | 18.54155409 | CS |
156 | -12.08 | -32.2219258469 | 37.49 | 39.49 | 13.48 | 30240 | 21.52172145 | CS |
260 | 13.3 | 109.826589595 | 12.11 | 46.32 | 11.58 | 39400 | 23.19818342 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions